On the ontogeny and physiology of regulatory T cells

Summary: Lymphocytes can interfere with the activity of other lymphocytes in a thousand and one ways. A particular subset of so-called regulatory CD4⁺ T cells is capable of controlling the activity of other lymphocytes in yet another way. Their function is primarily defined by the ability to protect the integrity of tissues and organs in vivo . This was demonstrated in experimental models of natural tolerance to peripheral tissues, transplantation tolerance and the regulation of immune responses promoted by exogenous antigens at the level of the intestinal mucosa. Moreover, regulatory T cells also play a major role in the systemic homeostatic mechanisms that control total lymphocyte numbers. There is good evidence to support the contention that a significant fraction of the naturally occurring regulatory T cells is generated in the thymus following selection mediated by high avidity T-cell receptor/ligand interactions. Symbolically, self-reactive regulatory T cells do represent the breakthrough of concepts challenging the long-lasting Burnetian dogma that all autoreactive cells should be eliminated or inactivated. Although clonal deletion of self-reactive cells is a fundamental process in T-cell development, controlled autoreactivity is part of the physiology of the immune system. Thus, autoreactive regulatory T cells also protect immunologists from the desperate hunting for the evil of horror autotoxicus .     

The Peer Aggressive and Reactive Behavior Questionnaire (Parb-Q): Measurement Invariance Across Italian and Brazilian Children, Gender and Age

This study examines measurement invariance, reliability and scores differences of the Peer Aggressive and Reactive Behaviors Questionnaire (PARB-Q) across Italian and Brazilian children, gender and age. Participants were 587 Italian and 727 Brazilian children, aged 7–13 years from 12 elementary schools. The PARB-Q is a brief self-report instrument composed by two scales that assess aggressive behavior and reactions to peer aggression. Multigroup confirmatory factor analyses indicated full measurement invariance of the PARB-Q across groups based on country, gender and age, providing support for the unidimensionality of the first scale (direct peer aggression, PA) and a 3-factor model of the second scale (reactive aggression, RA; seeking teacher support, STS; internalizing reaction, IR). Reliability indices were good for all factors. Italian children reported a higher frequency of PA and a lower frequency of IR than the Brazilian children. Boys scored higher than girls on PA and RA, while girls scored higher than boys on STS and IR. Younger children reported a lower frequency of PA and a higher frequency of STS than older children. Results provide support for structure validity and reliability of the PARB-Q in two countries and information on differences related to gender, age and culture in peer relationships in elementary school.     

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

BACKGROUND: Antiresorptive agents for the treatment of osteoporosis suppress bone remodeling and reestablish bone turnover at a lower rate to reduce bone loss. Recombinant teriparatide (human parathyroid hormone 1-34) stimulates bone formation, increases bone mass, and improves bone microarchitecture. We contrasted the effects of once-daily doses of 20 mug of teriparatide and 10 mg of alendronate sodium on bone mineral density (BMD) and markers of bone turnover. METHODS: Markers of bone turnover and areal BMD were assessed in 203 postmenopausal women with osteoporosis in an 18-month randomized parallel double-blind study; volumetric BMD was measured in a subset of women. RESULTS: Teriparatide significantly increased markers of bone turnover that peaked at 6 months (serum procollagen type I N-terminal propeptide, 218%, and urinary N-telopeptide corrected for creatinine, 58%; P<.001); alendronate significantly decreased the markers at 6 months (-67% and -72%, respectively; P<.001). At 18 months, areal and volumetric spine BMDs were significantly higher with teriparatide than with alendronate (10.3% vs 5.5% [P<.001] and 19.0% vs 3.8% [P<.01], respectively). Areal femoral neck BMD was significantly higher than baseline in the teriparatide and alendronate groups (3.9% and 3.5%, respectively). There were no significant differences in trabecular femoral neck BMD between the teriparatide and alendronate groups (4.9% and 2.2%, respectively). Cortical volumetric femoral neck BMD was significantly different between the teriparatide and alendronate groups (-1.2% and 7.7%, respectively; P = .05). CONCLUSION: Two distinct options for the management of osteoporosis lead to increases in BMD by opposite mechanisms of action on bone remodeling.     

倾斜试验中真假阳性的血流动力学和神经激素的研究

目的探讨血管迷走性晕厥患者和正常人倾斜试验阳性时不同的触发机制.方法倾斜试验采用静息平卧10min和80°直立30min.心脏监测仪连续监测心率和血压.试验阳性标准为晕厥先兆伴收缩压＜90imHg(1mmHg=O.133kPa)和(或)心率＜60次/min.超声心动图于基础平卧,直立2min和每隔3min直至试验结束时连续记录左室内径及降低速率,左室短轴缩短分数(SF)和每分心输出量(CO).同时测量平卧和直立时儿茶酚胺血浆浓度.试验分组为正常自愿者且倾斜试验阴性者8例(组1),平均年龄(34±5)岁;正常自愿者伴倾斜试验阳性者8例(组2),平均年龄(31±6)岁;原因不明晕厥伴倾斜试验阳性者16例(组3),平均年龄(30±9)岁.结果三组间年龄、性别以及基础状态下心率,平均动脉压、左室内径、SF、CO和儿茶酚胺血浆浓度无明显差异.直立时各组发生改变为(1)组3出现阳性反应时间明显短于组2[(10±4)min比(17±8)min,P＜0.05];(2)组3平均动脉压有即刻和持续性降低;(3)组3左室舒张末期内径降低速率明显大于其他两组;(4)SF在组3显著增强;(5)肾上腺素浓度在组3升高显著,试验终止时组1为(65±35)pg/ml,组2为(78±29)pg/ml,组3为(126±80)pg/ml(P均＜0.05);去甲肾上腺素在三组均增高但组间比较差异无显著性.结论血管迷走性晕厥患者和部分正常人倾斜试验虽均呈阳性反应,但血流动力学反应和触发机制不同.前者可能与外周血管张力异常,回心血量及左室容量聚降,肾上腺素分泌增多,促使左室收缩力增强触发Bezold-Jarisch神经反射有关;而后者在发生假阳性反应时,其左室内径和SF及肾上腺素血浆浓度与阴性组无明显不同.倾斜试验时血管迷走性晕厥患者肾上腺素分泌异常在血管舒缩反应损害和左室收缩力异常方面可能起恶化作用.     

Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation

OBJECTIVE: Regulatory CD4 T cells that express high levels of CD25 play a vital role in the maintenance of tolerance to self antigens and are required for the induction of nonresponsiveness to alloantigens. The long-term CD4+CD25high T-cell reconstitution after allogeneic stem cell transplantation is unknown. Here, we evaluated whether recovery of this T-cell subset might be linked to the establishment of full donor/recipient tolerance. METHODS: The frequency of CD4+CD25high T cells was determined by Fluorescence Activated Cell Sorter (FACS) analysis in 31 patients, with a mean follow-up of more than 31 months posttransplant. The expression levels of Foxp3 mRNA were assessed by quantitative real-time polymerase chain reaction (RT-PCR). RESULTS: Patients with or without graft-versus-host disease (GvHD) had significant and persistent CD4 T-cell lymphopenia. The relative frequency of CD25high cells and the expression levels of FoxP3 mRNA within this subset were similar between all patients and healthy controls. No significant difference was found in the number of Foxp3-expressing CD4+CD25high T cells in patients with or without GvHD. Finally, younger age and absence of previous GvHD were significantly linked to CD4+CD25high T-cell recovery. CONCLUSION: The low number of Foxp3-expressing CD4+CD25high T cells in grafted patients is not a specific default of this compartment but a consequence of global CD4 T-cell lymphopenia after allogeneic stem cell transplantation. Moreover, levels of Foxp3 mRNA in the CD25+ T-cell compartment do not allow predicting the development of GvHD in the long term.     

Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation

We report here on a preliminary human autologous transplantation study of retroviral gene transfer to bone marrow (BM) and peripheral blood (PB)-derived CD34-enriched cells. Eleven patients with multiple myeloma or breast cancer had cyclophosphamide and filgrastim-mobilized PB cells CD34-enriched and transduced with a retroviral marking vector containing the neomycin resistance gene, and CD34-enriched BM cells transduced with a second marking vector also containing a neomycin resistance gene. After high-dose conditioning therapy, both transduced cell populations were reinfused and patients were followed over time for the presence of the marker gene and any adverse effects related to the gene-transfer procedure. All 10 evaluable patients had the marker gene detected at the time of engraftment, and 3 of 9 patients had persistence of the marker gene for greater than 18 months posttransplantation. The marker gene was detected in multiple lineages, including granulocytes, T cells, and B cells. The source of the marking was both the transduced PB graft and the BM graft, with a suggestion of better long-term marking originating from the PB graft. The steady- state levels of marking were low, with only 1:1000 to 1:10,000 cells positive. There was no toxicity noted, and patients did not develop detectable replication-competent helper virus at any time posttransplantation. These results suggest that mobilized PB cells may be preferable to BM for gene therapy applications and that progeny of mobilized peripheral blood cells can contribute long-term to engraftment of multiple lineages.